在抗 PD-1 或抗 PD-L1 抗体治疗后，用于复发性和/或转移性头颈部鳞状细胞癌的卡铂和紫杉醇。

Carboplatin and paclitaxel after anti-PD-1 or anti-PD-L1 antibody therapy in recurrent and/or metastatic squamous cell carcinoma of head and neck.

机构信息

Virginia Tech Carilion School of Medicine, Roanoke, Virginia, USA.

School of Medicine, University of California San Francisco, San Francisco, California, USA.

出版信息

Head Neck. 2024 Feb;46(2):321-327. doi: 10.1002/hed.27580. Epub 2023 Nov 23.

DOI:10.1002/hed.27580

PMID:37997549

Abstract

BACKGROUND

The impact of concurrent chemotherapy and immunotherapy has been well characterized in patients with recurrent and metastatic head and neck squamous cell carcinoma (RM-SCCHN). Here, we report outcomes in patients treated sequentially with immune checkpoint inhibition (ICI) followed by carboplatin and paclitaxel.

METHODS

Patients with RM-SCCHN treated with ICI followed by carboplatin/paclitaxel at a single institution were identified retrospectively. ICI therapy history, p16, and PD-L1 status were collected. The best overall response was assessed by RECIST v1.1.

RESULTS

Twelve patients met inclusion criteria. Eight patients received pembrolizumab, three durvalumab, and one nivolumab. The median duration of ICI was 3.44 months, median PFS was 5.8 months, and median OS was 15.2 months. 66.7% of patients had an objective response on carboplatin/paclitaxel.

CONCLUSIONS

Carboplatin/paclitaxel can induce objective responses in patients with prior treatment with ICI and clinical outcomes in this small series compare favorably to those seen in ICI naïve patients.

摘要

背景

在复发性和转移性头颈部鳞状细胞癌（RM-SCCHN）患者中，同步化疗和免疫治疗的影响已得到充分描述。在这里，我们报告了在接受免疫检查点抑制剂（ICI）序贯治疗后再接受卡铂和紫杉醇治疗的患者的结果。

方法

回顾性地确定了在单一机构中接受 ICI 序贯卡铂/紫杉醇治疗的 RM-SCCHN 患者。收集了 ICI 治疗史、p16 和 PD-L1 状态。通过 RECIST v1.1 评估最佳总体反应。

结果

符合纳入标准的患者有 12 名。8 名患者接受了 pembrolizumab，3 名接受了 durvalumab，1 名接受了 nivolumab。ICI 的中位持续时间为 3.44 个月，中位无进展生存期为 5.8 个月，中位总生存期为 15.2 个月。66.7%的患者在接受卡铂/紫杉醇治疗后有客观反应。